Recombinant human NT-3 protein (Qk058)

[1] Bates, B. et al. Neurotrophin–3 is required for proper cerebellar development. Nat. Neurosci. 2, 115–117 (1999). doi: 10.1038/5669[2] Bibel, M. & Barde, Y.-A. Neurotrophins: key regulators of cell fate and cell shape in the vertebrate nervous system. Genes Dev. 14, 2919–2937 (2000). doi: 10.1101/gad.841400[3] Skaper, S. D. The Neurotrophin Family of Neurotrophic Factors: An Overview. in Neurotrophic Factors: Methods and Protocols (ed. Skaper, S. D.) 1–12 (Humana Press, 2012). doi:10.1007/978-1-61779-536-7_1[4] Maisonpierre, P. C. et al. NT-3, BDNF, and NGF in the developing rat nervous system: Parallel as well as reciprocal patterns of expression. Neuron 5, 501–509 (1990). doi.org/10.1016/0896-6273(90)90089-X[5] Mattson, M. P. & Scheff, S. W. Endogenous Neuroprotection Factors and Traumatic Brain Injury: Mechanisms of Action and Implications for Therapy. J. Neurotrauma 11, 3–33 (1994). doi: 10.1089/neu.1994.11.3[6] Goto, K. et al. Simple Derivation of Spinal Motor Neurons from ESCs/iPSCs Using Sendai Virus Vectors. Mol. Ther. Methods Clin. Dev. 4, 115 (2017). doi: 10.1016/j.omtm.2016.12.007[7] Schwartzentruber, J. et al. Molecular and functional variation in iPSC-derived sensory neurons. Nat. Genet. 50, 54–61 (2018). doi: 10.1038/s41588-017-0005-8[8] Marton, R. M. et al. Differentiation and maturation of oligodendrocytes in human three-dimensional neural cultures. Nat. Neurosci. 22, 484–491 (2019). doi: 10.1038/s41593-018-0316-9[9] Stebbins, M. et al. Human pluripotent stem cell–derived brain pericyte–like cells induce blood-brain barrier properties. Sci. Adv. 5, eaau7375 (2019). doi: 10.1126/sciadv.aau7375[10] Kamata, Y. et al. A robust culture system to generate neural progenitors with gliogenic competence from clinically relevant induced pluripotent stem cells for treatment of spinal cord injury. Stem Cells Transl. Med. 10, 398 (2021). doi: 10.1002/sctm.20-0269[11] Yun, W. et al. OCT4-induced oligodendrocyte progenitor cells promote remyelination and ameliorate disease. Npj Regen. Med. 7, 1–15 (2022). doi: 10.1038/s41536-021-00199-z[12] Caporali, A. & Emanueli, C. Cardiovascular Actions of Neurotrophins. Physiol. Rev. 89, 279 (2009). doi: 10.1152/physrev.00007.2008[13] Delgado, A. C. et al. Endothelial NT-3 Delivered by Vasculature and CSF Promotes Quiescence of Subependymal Neural Stem Cells through Nitric Oxide Induction. Neuron 83, 572–585 (2014). doi: 10.1016/j.neuron.2014.06.015[14] Vicario-Abejón, C., Owens, D., McKay, R. & Segal, M. Role of neurotrophins in central synapse formation and stabilization. Nat. Rev. Neurosci. 3, 965–974 (2002). doi: 10.1038/nrn988[15] Zeng, H. et al. Specification of Region-Specific Neurons Including Forebrain Glutamatergic Neurons from Human Induced Pluripotent Stem Cells. PLOS ONE 5, e11853 (2010). doi: 10.1371/journal.pone.0011853[16] Lin, L., Yuan, J., Sander, B. & Golas, M. M. In Vitro Differentiation of Human Neural Progenitor Cells Into Striatal GABAergic Neurons. Stem Cells Transl. Med. 4, 775–788 (2015). doi: 10.5966/sctm.2014-0083[17] Fernandopulle, M. S. et al. Transcription-factor mediated differentiation of human iPSCs into neurons. Curr. Protoc. Cell Biol. 79, e51 (2018). doi: 10.1002/cpcb.51[18] Gordon, A. et al. Long-term maturation of human cortical organoids matches key early postnatal transitions. Nat. Neurosci. 24, 331–342 (2021). doi: 10.1038/s41593-021-00802-y[19] Hu, B.-Y., Du, Z.-W., Li, X.-J., Ayala, M. & Zhang, S.-C. Human oligodendrocytes from embryonic stem cells: conserved SHH signaling networks and divergent FGF effects. Dev. Camb. Engl. 136, 1443–1452 (2009). doi: 10.1242/dev.029447[20] Wang, S. et al. Human iPSC-derived oligodendrocyte progenitors can myelinate and rescue a mouse model of congenital hypomyelination. Cell Stem Cell 12, 252–264 (2013). doi: 10.1016/j.stem.2012.12.002[21] Butte, M. J., Hwang, P. K., Mobley, W. C. & Fletterick, R. J. Crystal Structure of Neurotrophin-3 Homodimer Shows Distinct Regions Are Used To Bind Its Receptors,. Biochemistry 37, 16846–16852 (1998). doi: 10.1021/bi981254o[22] Rangasamy, S. B., Soderstrom, K., Bakay, R. A. E. & Kordower, J. H. Chapter 13 – Neurotrophic factor therapy for Parkinson’s disease. in Progress in Brain Research (eds. Björklund, A. & Cenci, M. A.) vol. 184 237–264 (Elsevier, 2010). doi: 10.1016/S0079-6123(10)84013-0[23] Keefe, K. M., Sheikh, I. S. & Smith, G. M. Targeting Neurotrophins to Specific Populations of Neurons: NGF, BDNF, and NT-3 and Their Relevance for Treatment of Spinal Cord Injury. Int. J. Mol. Sci. 18, 548 (2017). doi: 10.3390/ijms18030548[24] de Miranda, A. S., de Barros, J. L. V. M. & Teixeira, A. L. Is neurotrophin-3 (NT-3): a potential therapeutic target for depression and anxiety? Expert Opin. Ther. Targets 24, 1225–1238 (2020). doi: 10.1080/14728222.2020.1846720